...
首页> 外文期刊>Contemporary ob/gyn >cfDNA testing shows promise as primary aneuploidy screen
【24h】

cfDNA testing shows promise as primary aneuploidy screen

机译:cfDNA测试显示有望作为主要的非整倍性筛选

获取原文
获取原文并翻译 | 示例
           

摘要

An analysis conducted at 21 US centers suggests that maternal plasma cell-free DNA (cfDNA) testing should be considered as primary screening for fetal autosomal aneuploidy. The findings, from the Comparison of Aneuploidy Risk Evaluation (CARE) Study Group, were presented at the 18th International Conference on Prenatal Diagnosis and Therapy and published in Prenatal Diagnosis.
机译:在美国21个中心进行的分析表明,应将母体血浆无细胞DNA(cfDNA)检测作为胎儿常染色体非整倍性的初步筛选。来自非整倍性风险评估(CARE)研究组的研究结果在第18届国际产前诊断和治疗会议上发表,并发表在了产前诊断上。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号